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Abstract
Importance—The Universal Definition of Myocardial Infarction divides myocardial infarctions 
into different types. Type 1 myocardial infarctions result spontaneously from atherosclerotic 
plaque instability, whereas Type 2 myocardial infarctions occur in the setting of oxygen demand/
supply mismatch such as with severe hypotension. Type 2 myocardial infarctions are uncommon 
in the general population but the frequency of Type 2 myocardial infarctions in HIV-infected 
individuals is unknown.
Objective—To characterize myocardial infarctions including type; identify causes for Type 2 
myocardial infarctions, and compare demographic and clinical characteristics among HIV-infected 
individuals with Type 1 vs. Type 2 myocardial infarctions.
Setting/Design—Longitudinal HIV clinical care cohort at 6 U.S. sites.
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Events—Potential myocardial infarctions from 1996–2014 were identified in the centralized data 
repository using diagnoses and cardiac biomarkers. Sites assembled de-identified packets 
including physician notes, ECGs, procedure and clinical laboratory results. Two physician experts 
adjudicated each event, categorizing each definite/probable myocardial infarction as a Type 1 or 
Type 2 myocardial infarction, and identifying Type 2 myocardial infarction causes.
Results—Among 571 definite/probable myocardial infarctions, 288 (50%) were Type 2; sepsis 
and recent cocaine/crack use were the most common causes (35% and 14% of Type 2 myocardial 
infarctions, respectively). Individuals with Type 2 myocardial infarctions were younger on average 
and had lower CD4 cell counts, lipid levels, and Framingham risk scores than those with Type 1 
myocardial infarctions.
Limitations—Missing events or ascertainment bias is always a concern although we used both 
diagnoses and biomarkers to minimize this as much as possible. In addition, although we used a 
standardized approach with multiple expert adjudicators, distinguishing MI type with certainty can 
be difficult and there may be some misclassification of type.
Conclusions/Relevance—Approximately half of myocardial infarctions among HIV-infected 
individuals were Type 2. Type 2 myocardial infarctions were caused by heterogeneous clinical 
conditions including sepsis and cocaine/crack use. Demographic characteristics and cardiovascular 
risk factors among those with Type 1 and Type 2 myocardial infarctions differed, suggesting the 
need to specifically consider type among HIV-infected individuals to further understand 
myocardial infarction outcomes and to guide prevention and treatment.
Introduction
There are many unanswered questions regarding the risk of cardiovascular disease (CVD) 
including myocardial infarction (MI) in HIV-infected individuals. Studies have suggested 
that MI rates may be higher in HIV-infected vs. uninfected individuals1–4. HIV may impact 
lipid levels and endothelial function, leading to increased CVD risk5–7. Antiretroviral 
therapy (ART) has reduced HIV-related morbidity and mortality8–11 but some, particularly 
older ART agents, may increase CVD risk12–15. Many previous studies have used 
unadjudicated MI outcomes and have not differentiated MI types. These limitations may 
have contributed to conflicting findings regarding CVD risk in HIV-infected 
populations1,16,17.
The Universal Definition of MI classifies MI into 5 types according to the underlying 
mechanism of myocardial ischemia18. Type 1 MI events (T1MI) result spontaneously from 
atherosclerotic plaque instability. Type 2 MI events (T2MI) are secondary to causes other 
than atherosclerotic plaque rupture, including hypotension, hypoxia, and stimulant induced 
spasm resulting in increased oxygen demand or decreased supply. Type 3 MIs are deaths 
occurring with symptoms suggestive of MI and cardiac biomarkers were not measured. Type 
4 and 5 MIs occur in the setting of coronary revascularization procedures. Different MI 
types may portend a different prognosis and optimal medical management approach19.
Studies are needed to understand the impact of HIV and its treatment on the frequency of MI 
and MI types. Understanding MI types will require clearly defined clinical endpoints with 
accurate event identification and categorization. We developed an MI adjudication protocol 
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in the Centers for AIDS Research Network of Integrated Clinical Systems (CNICS) 
cohort20. We conducted this study to characterize MIs by type in a large and diverse cohort 
of HIV-infected individuals. We were interested in whether demographic and clinical 
characteristics including CVD risk factors would be similar for HIV-infected individuals 
with T1MI and T2MI. While estimates of T2MI incidence vary in the general population, 
T2MIs account for a minority of MIs21–28. We hypothesized that T2MIs in HIV may be 
common and would have distinct demographic and clinical characteristics including CVD 
risk factors compared with those with T1MI. If confirmed, these hypotheses would lend 
support to the idea that T1MI and T2MI are distinct clinical entities that represent different 
biological phenomena and should be treated as such among those with HIV.
Methods
Study cohort
The CNICS cohort includes HIV-infected individuals receiving care at 8 clinical sites across 
the United States29. Individuals who had an incident MI between 1/1/1996, and 3/1/2014 
from 6 sites (Johns Hopkins University; University of Alabama at Birmingham; University 
of California at San Diego; University of California at San Francisco; University of North 
Carolina at Chapel Hill; and University of Washington) were included in analyses. Sites 
received institutional review board approval for CNICS and written informed consent was 
obtained from participants.
Data Source
The CNICS data repository integrates comprehensive clinical data from all outpatient and 
inpatient encounters29. These data include laboratory test results such as cardiac biomarkers 
and lipid values; medications such as those used for diabetes, dyslipidemia, and 
hypertension; blood pressure values; and diagnoses29.
MI events
Potential MIs were identified retrospectively in the CNICS data repository by the presence 
of a clinical MI diagnosis or coronary intervention such as coronary artery bypass graft 
(CABG) or elevated troponin or CK-MB values20. For each potential MI, the site assembled 
de-identified packets that included available physician notes, ECGs, results from imaging 
studies, and laboratory results. These packets enabled adjudicators to review primary clinical 
data, eliminating errors that could potentially arise from local completion of case report 
forms. The names of antiretroviral medications were redacted to eliminate the possibility 
that knowledge of specific medications would influence evaluations of the potential MI. Two 
expert physician adjudicators independently reviewed each packet, followed by a 3rd 
reviewer if needed to resolve discrepancies. Reviewers considered ECGs, cardiac biomarker 
values, documented chest pain without another suggested cause, and wall motion 
abnormalities if imaging such as ventriculogram results were available. ECG criteria 
included the presence of evolving Q-waves, ST-elevations, and new left bundle branch block 
(LBBB) with different algorithms in the setting or absence of chest pain and cardiac 
biomarker elevations to determine Definite, Probable, or No MI. For example, a new LBBB 
would be classified as a Definite vs. Probable MI based on abnormal vs. equivocal cardiac 
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biomarkers. Reviewers entered standardized data into a web application regarding all MI 
criteria met including type of ECG abnormalities. Reviewers entered additional risk factor 
information including family history of CVD that was not already in the CNICS data 
repository.
Reviewers identified events that were likely falsely positive rather than true MIs. They 
identified specific potential reasons for false positive results such as isolated cardiac 
biomarker elevations without other evidence for MI in the setting of renal failure or 
pericarditis.
Reviewers categorized events as T1MI or T2MI, and identified potential causes for T2MI 
based on the clinical scenario such as an MI occurring while septic20. Patients with type 3 
MI were not included because by definition, cardiac biomarkers are unavailable. There were 
only 3 MIs that occurred in the setting of cardiac procedures, so Type 4 and 5 MIs are not 
further described. Reviewers also identified patients who did not meet criteria for an MI but 
had a coronary intervention including CABG surgery, percutaneous transluminal coronary 
angioplasty (PTCA), or stent placement. If an individual had both an MI and a coronary 
intervention as part of their incident event, the event was categorized by MI type. Only an 
individual’s first MI was included.
Statistical Analysis
We used Chi-squared and t-tests for categorical and continuous variables to assess 
differences in demographic and clinical characteristics among individuals with T1MI or 
cardiac intervention versus T2MI. We considered age, sex, self-reported race/ethnicity and 
risk factor for HIV transmission, body mass index (BMI) closest to the MI, CD4 cell count 
and HIV-1 viral load (VL) closest to the MI, and CD4 nadir and peak HIV VL. We 
considered the most recent lipid values prior to the MI including total cholesterol (TC), high 
density lipoprotein cholesterol (HDL), non-high density lipoprotein cholesterol (non-HDL), 
low density lipoprotein cholesterol (LDL), and triglycerides. We also considered statin and 
anti-hypertensive medication use. As in prior studies30, we defined diabetes based on any of 
the following criteria prior to the MI: a) hemoglobin A1c ≥6.5 OR b) use of a diabetes-
specific medication such as insulin OR c) use of a diabetes-related medication frequently but 
not exclusively used to treat diabetes (e.g. biguanides) in the setting of also having a diabetes 
diagnosis30. A diabetes diagnosis alone did not meet the definition. We computed and 
compared 10-year coronary heart disease (CHD) risk scores from the Framingham Risk 
Assessment Tool31 using mean and categorical scores (≤10 low risk, 10–20 intermediate 
risk, and ≥20 high risk). We examined smoking status.
We also conducted a sensitivity analysis comparing those with T1MI with individuals who 
had a coronary intervention without an MI.
Results
Of 26,909 HIV-infected patients evaluated during the ascertainment period, 1689 met 
ascertainment criteria for a potential MI at least once. Among these, 571 (28% of 2037) 
events were adjudicated as an MI, of which 65% (370/571) were classified as Definite MI, 
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and 35% (201/571) as Probable MI. Among the definite/probable MIs, 50% were T1MI and 
50% T2MI. An additional 79 (4%) events did not meet MI criteria, but patients had severe 
enough atherosclerotic disease that they underwent a coronary intervention such as a CABG. 
Among those with an adjudicated MI, 77% were men, and the median age was 49 
(interquartile range IQR 43–55), and the current median CD4 cell count was 326 cells/mm3 
(IQR 136–571). The current CD4 count was drawn a median of 47 days before the MI (IQR 
15–108 days).
A higher proportion with a T2MI were under 40 years of age, female, African-American, not 
on ART, and their HIV transmission risk factor was intravenous drug use compared with 
those with a TIMI (Table 1).
A higher proportion of those with a T2MI also had a low CD4 count and high HIV VL 
compared with those with a T1MI (Table 1) with a median current CD4 cell count of 230 
cells/mm3 vs. 383 cells/mm3 for those with a T1MI.
Diabetes and hypertension were equally prevalent among those with T1MI vs. T2MI (Table 
2). However, a higher proportion of individuals with a T1MI were receiving a statin prior to 
the event and had higher mean TC, non-HDL, and LDL levels compared with those who had 
a T2MI. Individuals with a T1MI were also more likely to be current smokers. Those with a 
T1MI had a higher mean 10-year Framingham CHD risk score than those with a T2MI 
(Table 2). Intermediate Framingham risk scores were present in 21% of those with T1MI vs. 
16% with T2MI, and high-risk scores were present in 12% of T1MI vs. 8% of T2MI (p 
value=0.047).
Sepsis (35%), cocaine or other drug-induced vasospasm (14%) and hypertensive emergency 
(10%) were the most frequently identified likely causes of T2MI (Table 3). A diverse array 
of clinical conditions were identified for the remaining T2MIs.
Compared with patients with a T1MI, those with a coronary intervention without meeting 
MI criteria were more likely to be male, had a lower VL, and a higher 10-year Framingham 
CHD risk score but did not differ on other HIV-specific or CVD risk factors from those with 
a T1MI (eTables 1–2).
Discussion
We examined MI types in a large, nationally distributed HIV cohort. T2MIs were common, 
comprising half of MIs. We identified characteristics that differed between individuals with 
T1MI and T2MI. On average, individuals who had a T2MI were younger, had a lower CD4 
count and higher VL, and fewer traditional CVD risk factors including less dyslipidemia, 
lower current smoking rates, and lower CHD risk scores. Individuals with a T2MI were 
significantly different from those with T1MI with regard to demographic and clinical 
characteristics, particularly CVD risk factors. Our results suggest that in HIV-infected 
individuals, T1MI and T2MI may represent distinct clinical entities that require different 
approaches to prevention and treatment, as noted in the general population19. This study is 
the first to report a high proportion of T2MI occurring among HIV-infected individuals.
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T1MI vs. T2MI in HIV-infected vs. other populations
Distinguishing T1MI from T2MI has been recommended since 2007 by the second 
Universal Definition of MI18 and endorsed by major cardiology societies32 but can be 
challenging19. Categorization of MI by type has increased over time, but the International 
Classification of Diseases (ICD) coding system lacks distinct categories for T2MI32 likely 
limiting capture in clinical settings. However, non-specific ICD-9 411.89 and ICD-10 I24.8 
codes “other acute and subacute forms of ischemic heart disease” have been used for this 
purpose33. Lack of data on MI type has been attributed to the relatively recent introduction 
of the Universal Definition of MI, presumed under-reporting of T2MI, and lack of 
consistency in T2MI criteria32.
Despite these limitations, studies have found that T2MI are much less common than T1MI 
in most populations consisting of <2–26% of MIs, depending on adjudication methodology 
and population22–28, usually <10% of all MIs23–28. In a Danish study of hospitalized 
patients, there were 541 MIs of which 26% were T2MI22. In contrast, the proportion of 
T2MI in our HIV population was almost twice as high as the Danish study. This may be due 
to an increased likelihood of bacteremia and infections resulting in sepsis and increased 
prevalence of cocaine use in those with HIV. In addition, the Danish study did not exclude 
individuals with prior MI: 27% in the Danish study with T2MI had a history of a prior MI, 
17% prior PCI, and 10% prior CABG. In contrast, we focused on initial events. While more 
data are needed, our findings suggest that the proportion of T2MI among HIV-infected 
individuals is higher than in many other populations. These differences have important 
clinical implications19. Prevention and treatment of atherosclerotic CVD, including statin 
use, anti-platelet agents, and coronary procedures have been studied and disseminated in 
T1MI guidelines however optimal management and prevention of T2MIs is unclear.
Causes of T2MI
We found that almost half of T2MIs were in the setting of sepsis or illicit drug-induced 
vasospasm, most often cocaine. Cocaine increases myocardial oxygen demand by increasing 
blood pressure, heart rate, and myocardial contractility and can also decrease myocardial 
blood supply by inducing coronary vasoconstriction34. Factors that lead to T2MI have not 
been well characterized in the general population. The most common presumed T2MI 
causes in the Danish study were anemia, arrhythmias, and respiratory failure22. A New York 
study found surgery, anemia, and sepsis were common33. Arrhythmias were also a common 
presumed T2MI cause in several general population studies21,28,35. In contrast, we found 
sepsis and cocaine use were common with T2MI. These results suggest that HIV-infected 
individuals have a very different set of presumed T2MI causes than the general 
population21,28,35.
T1MI vs. T2MI
We found substantial differences in demographic and clinical characteristics among HIV-
infected individuals who experienced a T1MI vs. T2MI. Higher proportions with a T2MI 
were younger, female, and had poorer control of their HIV infection as measured by current 
CD4 and VL. This contrasts with HIV-uninfected population studies in which patients with 
T2MI were older than those with T1MI21,28. In the general population, people with T2MI 
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tend to be seriously ill. We similarly found that those with a T2MI tended to be sicker in 
terms of HIV status than those with a T1MI.
Adjudication
Central adjudication is preferable to local adjudication with or without secondary central 
review20. Clinical MI definitions have changed over time36. In particular, events that used to 
be characterized as unstable angina would now be considered an MI. We therefore 
ascertained potential MIs using cardiac biomarkers in addition to diagnoses. While 
diagnoses alone such as from billing data are commonly used for ascertainment, possibly 
with concomitant verification using other data elements4,16,37–40, the sensitivity of this 
approach is not optimal41. We have previously demonstrated that using clinical diagnoses 
alone results in missing substantial numbers of T2MI in particular20. This is not surprising 
since there is no relevant ICD code to document myocardial injury due to severe extra-
cardiac causes such as sepsis32,42. Experts have advocated the development of distinct T2MI 
diagnostic codes19. Studies with cardiac biomarkers in their ascertainment criteria therefore 
likely do a better job capturing T2MIs vs. those that rely on diagnoses alone. It is worth 
noting that the Universal MI Definition has not established what is a significant level of 
hypertension, hypotension, etc. therefore T2MI must rely on clinical judgment21.
Strengths
CNICS is large and geographically and ethnically diverse with comprehensive clinical data. 
We ascertained for potential events using both abnormal cardiac biomarkers and clinical 
diagnoses in order to increase the sensitivity of ascertainment and more fully capture the MI 
burden in HIV. However, this may make comparing rates of T2MI to other cohorts with a 
less sensitive approach challenging. Adjudication facilitates capturing MI type and potential 
causes of T2MI.
Limitations
Our study has limitations. Silent T1MI can be missed and T2MI may be missed in critically 
ill people in whom cardiac biomarkers are not assessed. We did not systematically examine 
ECGs to identify silent events, however this approach has been shown to have a low 
detection probability43. Ascertainment may be incomplete for events that occur outside 
CNICS sites although we request medical records. We used troponin assays, however they 
have become more sensitive over time and are not biologically equivalent due to biochemical 
differences in assays and reference populations used to determine upper reference limits44. 
While we categorized MI by type using carefully reviewed clinical data, there is debate 
regarding what criteria should be used to categorize an event as T2MI32 and correctly 
classifying falsely positive events vs. T2MI can be difficult. However, events were reviewed 
independently by two physicians, and resolved by a third reviewer in case of disagreement, 
ensuring consistency in our approach to diagnosis and classification. Cardiac catheterization 
to verify obstructive coronary disease was frequently not done for T1MI and rarely done for 
T2MI. It is therefore unknown whether most of those with T2MI had obstructive disease. 
Lastly, because our study is the first to describe MI types in HIV, the findings have not been 
replicated although the pattern of ~ half T1MI vs. T2MI was seen across the 6 CNICS sites.
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T2MI are increasingly recognized in the general population and additional research is 
needed to better define and manage these events45. The importance of applying ECG 
classifications such as ST segment elevation MI (STEMI) vs. non-ST segment elevation MI 
(NSTEMI) to categorizing T2MI is unclear as these classifications are intended to help 
guide clinical reperfusion therapy decisions in T1MI32.
Research is needed to better understand the complex relationship between traditional and 
HIV-specific CVD risk factors, the genetic predisposition to develop MI and the potential 
interactions with ART, and the role of behavioral factors. Further evaluation to understand 
the role of sepsis and risk for T2MI is needed. Such information can guide interventions to 
alter these relationships and improve prognosis, as well as improve risk prediction and risk-
reduction strategies. Differentiating MI type is important clinically as it is likely that optimal 
interventions, such as use of anticoagulation therapy, will differ by type. It is unclear if 
T1MI or T2MI will decrease in the current era now that ART initiation is earlier and with 
potentially less metabolically active regimens. Classification of MI type will result in a 
better understanding of these important outcomes among those with HIV.
Conclusions
Our large cohort study of HIV-infected individuals across the US demonstrates that 
approximately half of MIs are T2MI. Individuals with T2MI were younger and sicker in 
terms of their HIV but with lower Framingham CHD risk scores than those with T1MI 
suggesting these events may be due to different mechanisms among different populations. 
These findings have important implications for studying MIs, understanding the higher MI 
rates and extent MI burden can be reduced by CVD risk factor modification among HIV-
infected individuals, particularly given the unknown role, if any, of atherosclerosis in T2MI. 
Understanding MI types may help clarify unanswered questions regarding risk factors, risk 
scoring, and prognosis. Most importantly, these findings are important clinically, as T1MI 
and T2MI may require different approaches for prevention and treatment in HIV-infected 
individuals.
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Table 1









Male 293 (81) 207 (72)
Female 69 (19) 81 (28)
Age, years 0.01
<40 32 (9) 47 (16)
40–49 152 (42) 106 (37)
50–59 125 (35) 99 (34)
60–69 43 (12) 22 (8)
≥70 10 (3) 14 (5)
Race/Ethnicity <0.001
White 171 (47) 65 (23)
African-American 156 (43) 202 (70)
Hispanic 19 (5) 14 (5)
Other/unknown 16 (4) 7 (2)
HIV Transmission Risk Factor <0.001
Heterosexual 101 (28) 93 (32)
Men who have sex with men 166 (46) 75 (26)
Injection drug use 78 (22) 107 (37)
Other/unknown 17 (5) 13 (5)
Antiretroviral therapy <0.001
Yes 271 (75) 154 (53)
No 91 (25) 134 (47)
CD4 count closest to event (cells/μl) <0.001
0–200 94 (26) 128 (44)
201–350 72 (20) 57 (20)
>350 195 (54) 103 (36)
CD4 cell count nadir (cells/μl) 0.02
0–200 212 (59) 199 (69)
201–350 79 (22) 48 (17)
>350 70 (19) 41 (14)





















HIV-1 RNA closest to event <0.001
<400 217 (60) 127 (44)
400–10,000 47 (13) 49 (17)
10,000–100,000 63 (17) 59 (20)
>100,000 34 (9) 53 (18)
HIV-1 RNA, peak 0.02
<400 43 (12) 20 (7)
400–10,000 35 (10) 31 (11)
10,000–100,000 112 (31) 70 (24)
>100,000 171 (47) 167 (58)
*
T1MI also includes patients with coronary interventions
One patient was missing CD4 and VL data prior to the MI and was excluded from those rows
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Table 2








Diabetes (N, %) 0.5
No 286 (79) 221 (77)
Yes 76 (21) 67 (23)
Blood pressure mean (mean, SD) 0.3
Systolic (mmHg) 132 (23) 130 (24)
Anti-hypertensive medication (N, %) 0.6
No 164 (45) 124 (43)
Yes 198 (55) 164 (57)
Lipid Levels mean (mean, SD)
HDL (mg/dL) 40 (15) 42 (19) 0.2
LDL (mg/dL) 108 (43) 87 (40) <0.001
Non-HDL (mg/dL) 149 (52) 125 (60) <0.001
Total Cholesterol (mg/dL) 190 (54) 167 (63) <0.001
Triglycerides (mg/dL) 227 (182) 208 (272) 0.4
Statin use (N, %) <0.001
No 244 (67) 232 (81)
Yes 118 (33) 56 (19)
Smoking (N, %) 0.005
No 125 (35) 136 (47)
Former 56 (15) 36 (13)
Current 181 (50) 116 (40)
Body mass index (mean, SD)
BMI (kg/m2) 26 (5) 24 (6) 0.001
Risk Score (mean, SD) <0.001
Framingham CHD (% 10 year event risk) 10 (8) 8 (7)
*
T1MI also include cardiac interventions such as coronary artery bypass graft (CABG) surgery
HDL: high density lipoprotein cholesterol; LDL: low density lipoprotein cholesterol; non-HDL; non-high density lipoprotein cholesterol
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Table 3
Most likely causes for Type 2 MI among HIV-infected individuals
Cause Number, %
Sepsis/bacteremia 100, 35
Cocaine or other illicit drug induced 39, 14
Hypertensive urgency/emergency 28, 10
Respiratory failure 26, 9
Non-coronary cardiac* 23, 8
Other/unknown 16, 6
Hypotension** 15, 5
Procedure related*** 12, 4






Non-coronary cardiac causes include non-atherosclerotic causes such as related to a congestive heart failure and cardiac tumor
**
Hypotension not due to sepsis, GI bleed, overdose or other listed causes
***
These are not cardiac procedures (which typically get classified as a Type 4 MI), instead these are events that occur in the setting of surgeries 
such as abdominal surgery and lower extremity amputation
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